Niagen Bioscience (NAGE) Cash from Investing Activities (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Cash from Investing Activities of $5.2 million for Q1 2026, up 16490.62% year-over-year from N/an in Q1 2025, and up 5293.07% quarter-over-quarter from -$101000.0 in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Cash from Investing Activities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Cash from Investing Activities for 14 consecutive years, with $5.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 16490.62% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.0 million (up 3820.15% YoY), while the FY2025 annual figure was -$292000.0, down 104.2% from the prior year.
- Cash from Investing Activities grew to $5.2 million in Q1 2026 per NAGE's latest filing, from -$101000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.2 million in Q1 2026 and bottomed at -$172000.0 in Q4 2022.
- Historically, Cash from Investing Activities has averaged $254882.4 across 5 years, with a median of -$32000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 8500.0% — and 2026, when it surged 16490.62%.
- Niagen Bioscience's Cash from Investing Activities stood at -$172000.0 in 2022, then jumped by 87.79% to -$21000.0 in 2023, then slumped by 228.57% to -$69000.0 in 2024, then slumped by 46.38% to -$101000.0 in 2025, then jumped by 5293.07% to $5.2 million in 2026.
- Business Quant data shows NAGE's Cash from Investing Activities at $5.2 million in Q1 2026, -$101000.0 in Q4 2025, and -$24000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | -92,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -92,000.00 |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | -101,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -135,000.00 |
| Mar 31, 2025 | -32,000.00 |
| Dec 31, 2024 | -69,000.00 |
| Sep 30, 2024 | -21,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -41,000.00 |
| Dec 31, 2023 | -21,000.00 |
| Sep 30, 2023 | -26,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | -91,000.00 |
| Dec 31, 2022 | -172,000.00 |
| Sep 30, 2022 | -52,000.00 |
| Jun 30, 2022 | -85,000.00 |
| Mar 31, 2022 | -25,000.00 |
| Dec 31, 2021 | -2,000.00 |
| Sep 30, 2021 | -96,000.00 |